BioSpace News Archive

BioVie Inc. entered into a debt facility with Avenue Venture Opportunities Fund, L.P. and Avenue Venture Opportunities Fund II, L.P.

Beyond Air, Inc. announced the appointment of Dr. Andrew Colin to the newly created position of Chief Medical Officer, effective December 1, 2021.

Zogenix today announced the U.S. Food and Drug Administration (FDA) has accepted for filing and granted Priority Review to the company’s supplemental New Drug Application (sNDA) for the use of FINTEPLA ® for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS).

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), today announced that the 24th Biennial HEP DART 2021 Frontiers in Drug Development for Hepatology meeting being held December 5-9 in Cabo San Lucas, Mexico.

Harmony Biosciences Holdings, Inc. (“Harmony”) (Nasdaq: HRMY), today announced that the U.S. Food and Drug Administration (FDA) has accepted an Investigational New Drug (IND) application for pitolisant for the treatment of idiopathic hypersomnia (IH).

Australian clinical-stage drug development company Noxopharm (ASX:NOX) has in-licensed novel RNA technology developed by Hudson Institute of Medical Research,

Tranquis Therapeutics today announced it has strengthened its management team with the addition of Faisal Shawwa, MBA, as Senior Vice President of Finance and Administration and Janet Hurt, MPH, as Senior Vice President of Clinical Evidence Generation.

CytoDyn Inc. today announced it has completed submission of all the major sections of CMC modules to FDA, some remaining supporting documentation will be submitted under Regional Information before the end of this week.

Milestone Scientific Inc., a leading developer of computerized drug delivery instruments, that provide painless and precise injections, announced that Dr. Miguel de la Garza has begun incorporating the CompuFlo® Epidural instrument into his practice for pain management, following approval by Surgery Partners, one of the largest and growing surgical services business in the country.

LumiraDx (Nasdaq: LMDX) announced today that the intended use for its Food and Drug Administration (FDA) Emergency Use Authorization (EUA) SARS-CoV-2 RNA STAR Complete, a rapid, nucleic acid amplification technology for high sensitivity, high throughput COVID-19 testing has been reissued.